<ul><li>Switzerland-based techbio company, Hedera Dx, has secured €15M in a Series A funding round led by Vsquared Ventures and new investor Tesi to advance cancer care globally.</li><li>Hedera Dx aims to address gaps in oncology care by offering solutions that enhance hospital-based testing, increase access to targeted therapies, and provide real-world data insights for precision oncology.</li><li>The company's liquid biopsy testing solutions are already in use in 11 European countries, enabling local hospital laboratories to conduct sophisticated molecular diagnostics efficiently.</li><li>Investors like Vsquared Ventures and Tesi back Hedera Dx's mission to revolutionize cancer care by making precision medicine more widely accessible and driving innovation in oncology treatments.</li></ul>

Swiss-based Hedera Dx bags €15M to help hospitals offer better cancer tests and treatments globally

Discover more